Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: A randomized multicenter trial

Liver

Volumn 20, Issue 6, 2000, Pages 427-436

  Berg, Thomas ^a,g   Hoffmann, Robert M ^b   Teuber, Gerlinde ^c   Leifeld, Ludger ^d   Lafrenz, Michael ^e   Baumgarten, Renate ^f   Spengler, Ulrich ^d   Zeuzem, Stefan ^c   Pape, Gerd R ^b   Hopf, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f Vivantes Klinikum Prenzlauer Berg   (Germany)

^g HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Combination therapy; Hepatitis C; Virological treatment response; Virus kinetics

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PATIENT; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TINNITUS;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIREMIA;

EID: 0034529686     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020006427.x     Document Type: Article

References (34)

1. Randomised, double blind, placebo-controlled trial of interferon-α-2b with and without ribavirin for chronic hepatitis C
2. Randomized trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
3. Interferon alpha-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C
4. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C
5. Molecular mechanisms of action of ribavirin
6. Broad spectrum activity of virazole: 1-beta-D-ribofuranosyl-1, 2, 3-triazole-3-carboxamide
7. Ribavirin treatment for chronic hepatitis C
8. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C
9. Ribavirin inhibits viral induced macrophage production of TNF, IL-1, the procoagulant fg12 prothombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
10. Hepatitis C viral dynamics and the antiviral efficacy of interferon-α therapy
11. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alpha
12. National Institutes of Health consensus development conference panel statement: Management of hepatitis C
13. Behandlung der chronischen Virushepatitis B/D und der akuten und chronischen Hepatitis C. Konsensus der Deutschen Gesellschaft fur Verdauungs- und Stoffwechselerkrankungen
14. Prediction of response to interferon treatment of chronic hepatitis C
15. Response to higher doses of interferon alpha-2b in patients with chronic hepatitis C: A randomized multicenter trial
16. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?
17. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
18. Classification of chronic hepatitis: Diagnosis, grading and staging
19. Histological classifciation and quantitation of the severity of chronic hepatitis: Keep it simple
20. Sarcoidosis associated with interferon-α therapy for chronic hepatitis C
21. Interferon alpha-2b alone or in combination with ribavirin for the treatment relapse of chronic hepatitis C
22. Factors predictive of a beneficial response to therapy of hepatitis C
23. Chronic hepatitis C and interferon alpha therapy: Predictors of long-term response
24. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for responses to interferon treatment
25. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM
26. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha
27. Preditive factors in the response to interferon therapy in chronic hepatitis C
28. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C
29. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C
30. Serial assay of hepatitis C virus RNA is serum for predicting response to interferon-α therapy
31. Early loss of hepatitis C virus RNA can predict sustained response to interferon therapy in patients with chronic hepatitis C
32. Viral kinetic can predict early response to alpha-interferon in chronic hepatitis C
33. Comparison of quantitative HCV RNA assays in chronic hepatitis C
34. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quanatiplex HCV RNA assay versions 1 and 2, Roche Monitor assay and in-house limiting dilution method